Current knowledge of small cell lung cancer transformation from non-small cell lung cancer

IF 12.1 1区医学 Q1 ONCOLOGY Seminars in cancer biology Pub Date : 2023-09-01 DOI:10.1016/j.semcancer.2023.05.006

Giuseppe Giaccone, Yongfeng He

引用次数: 6

Abstract

Lung cancer is the leading cause of cancer related death, and is divided into two major histological subtypes, non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Histological transformation from NSCLC to SCLC has been reported as a mechanism of treatment resistance in patients who received tyrosine kinase inhibitors (TKIs) targeting EGFR, ALK and ROS1 or immunotherapies. The transformed histology could be due to therapy-induced lineage plasticity or clonal selection of pre-existing SCLC cells. Evidence supporting either mechanism exist in the literature. Here, we discuss potential mechanisms of transformation and review the current knowledge about cell of origin of NSCLC and SCLC. In addition, we summarize genomic alterations that are frequently observed in both “de novo” and transformed SCLC, such as TP53, RB1 and PIK3CA. We also discuss treatment options for transformed SCLC, including chemotherapy, radiotherapy, TKIs, immunotherapy and anti-angiogenic agents.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

目前对小细胞肺癌从非小细胞肺癌转化的认识

癌症是癌症相关死亡的主要原因，可分为两种主要的组织学亚型，即癌症（NSCLC）和癌症小细胞肺癌（SCLC）。据报道，在接受靶向EGFR、ALK和ROS1的酪氨酸激酶抑制剂（TKIs）或免疫疗法的患者中，从NSCLC到SCLC的组织学转变是治疗耐药性的一种机制。转化的组织学可能是由于治疗诱导的谱系可塑性或先前存在的SCLC细胞的克隆选择。支持这两种机制的证据都存在于文献中。在这里，我们讨论了潜在的转化机制，并回顾了目前关于NSCLC和SCLC起源细胞的知识。此外，我们总结了在“从头”和转化的SCLC中经常观察到的基因组改变，如TP53、RB1和PIK3CA。我们还讨论了转化性小细胞肺癌的治疗方案，包括化疗、放疗、TKIs、免疫疗法和抗血管生成药物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Seminars in cancer biology 医学-肿瘤学

CiteScore

26.80

自引率

4.10%

发文量

347

审稿时长

15.1 weeks

期刊介绍： Seminars in Cancer Biology (YSCBI) is a specialized review journal that focuses on the field of molecular oncology. Its primary objective is to keep scientists up-to-date with the latest developments in this field. The journal adopts a thematic approach, dedicating each issue to an important topic of interest to cancer biologists. These topics cover a range of research areas, including the underlying genetic and molecular causes of cellular transformation and cancer, as well as the molecular basis of potential therapies. To ensure the highest quality and expertise, every issue is supervised by a guest editor or editors who are internationally recognized experts in the respective field. Each issue features approximately eight to twelve authoritative invited reviews that cover various aspects of the chosen subject area. The ultimate goal of each issue of YSCBI is to offer a cohesive, easily comprehensible, and engaging overview of the selected topic. The journal strives to provide scientists with a coordinated and lively examination of the latest developments in the field of molecular oncology.

期刊最新文献

Extracellular vesicles and biomarker discovery cGAS/STING signalling pathway in senescence and oncogenesis Combined targeting of senescent cells and senescent macrophages: A new idea for integrated treatment of lung cancer Editorial Board Erratum to “RNA regulatory mechanisms controlling TGF-β signaling and EMT in cancer” [Semin. Cancer Biol. 102–103 (2024) 4–16]